Anti-Terrorism, Crime and Security Act 2001

Total Page:16

File Type:pdf, Size:1020Kb

Anti-Terrorism, Crime and Security Act 2001 Anti-terrorism, Crime and Security Act 2001 Part 7 of the Anti-Terrorism, Crime and Security Act 2001 is concerned with the security of dangerous substances that may be targeted or used by terrorists. These substances are listed in Schedule 5 of the Act. The Schedule was amended in 2007. The current list is shown below and includes viruses, rickettsiae, fungi, bacteria, toxins and animal pathogens. The toxins are also included in HAZDAT. The provisions set out in Part 7 (and Schedules 5 and 6) place an obligation on managers of laboratories and other premises holding stocks of specified disease-causing micro-organisms and toxins to notify their holdings, and to comply with any reasonable security requirements which the police may impose. It also requires managers of laboratories and other premises, on request, to furnish the police with details of people with access to the dangerous substances held there. The Secretary of State is given power to direct that a named individual must not be allowed access to such disease strains or the premises in which they are held. Reporting etc, is co-ordinated through the University Health and Safety Unit. VIRUSES Chikungunya virus Mobala virus Congo-crimean haemorrhagic Monkey pox virus fever virus Mucambo virus Dengue fever virus Murray Valley encephalitis Dobrava/Belgrade virus virus Eastern equine encephalitis Ndumu virus virus Nipah virus Ebola virus Omsk haemorrhagic fever Everglades virus virus Getah virus Polio virus Guanarito virus Powassan virus Hantaan virus Rabies virus Hendra virus (Equine Rift Valley fever virus morbillivirus) Rocio virus Herpes simiae (B virus) Sabia virus Influenza viruses (pandemic Sagiyama virus strains) Sin Nombre virus Japanese encephalitis virus St Louis encephalitis virus Junin virus Tick-borne encephalitis virus Kyasanur Forest virus (Russian Spring-Summer Lassa fever virus encephalitis virus) Louping ill virus Variola virus Lymphocytic choriomeningitis Venezuelan equine virus encephalitis virus Machupo virus West Nile fever virus Marburg virus Western equine encephalitis Mayaro virus virus Middleburg virus Yellow fever virus RICKETTSIAE Coxiella burnetii Rickettsia prowazeki Rickettsia rickettsii Rickettsia typhi (mooseri). BACTERIA Bacillus anthracis Francisella tularensis Brucella abortus Multiple-drug resistant Salmonella paratyphi Brucella canis Mycobacterium tuberculosis Brucella melitensis Salmonella paratyphi A, B, C Brucella suis Salmonella typhi Burkholderia mallei (Pseudomonas mallei) Shigella boydii Burkholderia pseudomallei (Pseudomonas Shigella dysenteriae pseudomallei) Shigella flexneri Chlamydophila psittaci Vibrio cholerae Clostridium botulinum Yersinia pestis Clostridium perfringens Enterohaemorrhagic Escherichia coli, serotype 0157 and verotoxin producing strains FUNGI Cladophialophora bantiana Cryptococcus neoformans TOXINS TOXIN - CAS NUMBER Abrin Modeccin toxin Shiga and Shiga-like toxins Abrin - 1393-62-0 Shiga toxin DNA (Escherichia coli strain KY-019 clone Botulinum toxins pKTN1054 Shiga-like toxin SLT-II subunit A Botulin D - 93384-46-4 gene plus Shiga-like toxin SLT-II subunit B Botulinum toxin A - 93384-43-1 gene) - 153834-56-1 Botulinum toxin B DNA (Escherichia coli strain KY-019 clone Botulinum toxin F pKTN1054 Shiga-like toxin SLT-II subunit A gene) - 153834-58-3 Clostridium botulinum toxin DNA (Escherichia coli strain KY-019 clone pKTN1054 Shiga-like toxin SLT-II subunit B gene) - 153834-60-7 Clostridium perfringens toxins DNA (Escherichia coli strain TK-051 clone Clostridium botulinum neurotoxin pKTN1050 Shiga-like toxin SLT-II subunit A Clostridium perfringens, epsilon toxin gene plus Shiga-like toxin SLT-II subunit B Clostridium perfringens, type A enterotoxin gene) - 153834-57-2 DNA (Escherichia coli strain TK-051 clone Conotoxin pKTN1050 Shiga-like toxin SLT-II subunit A Conotoxin - 123210-68-4 gene) - 153834-59-4 Verotoxin 1 (Shiga shigella B subunit) - Modeccin 620190-09-2 Modeccin - 65988-88-7 Staphylococcal enterotoxins Ricin Staphylococcal enterotoxin A (Staphylococcus Ricin - 9009-86-3 aureus gene SEA) - 915245-87-3 Staphylococcal enterotoxin B (Staphylococcus Saxitoxin aureus aureus strain COL gene seb) - 811333- Saxitoxin - 35523-89-8 16-1 Staphylococcal enterotoxin C-bovine (Staphylococcus aureus host cattle gene sec- Any reference to a micro-organism or toxin bov) - 349587-80-0 includes: Staphylococcal enterotoxin E (Staphylococcus aureus) - 197981-85-4 (a) any genetic material containing any nucleic acid sequence Tetrodotoxin - associated with the pathogenicity of the Tetrodotoxin - 4368-28-9 micro-organism or - for the coding of the toxin; and Viscum Album Lectin 1 (Viscumin) Viscum Album Lectin 1 - 83590-17-4 (b) any genetically modified organism containing any such sequence. Volkensin toxin Volkensin toxin - 91933-11-8 Any reference to a toxin includes subunits of the toxin. ANIMAL PATHOGENS African horse sickness virus Lumpy skin disease virus African swine fever virus Newcastle disease virus Bluetongue virus Peste des petits ruminants virus Classical swine fever virus Rift Valley fever virus Contagious bovine pleuropneumonia Rabies and rabies-related Lyssaviruses Foot and mouth disease virus Rinderpest virus Goat pox virus Sheep pox virus Hendra virus (Equine morbillivirus) Swine vesicular disease virus Highly pathogenic avian influenza (HPAI) as Vesicular stomatitis virus defined in Annex I(2) of Council Directive 2005/94/EC(a) Any reference to a micro-organism includes: (a) intact micro-organisms; (b) micro-organisms which have been genetically modified by any means, but retain the ability to cause serious harm to animal health; (c) any nucleic acid derived from a micro- organism listed in this Schedule (synthetic or naturally derived, contiguous or fragmented, in host chromosomes or in expression vectors) that can encode infectious or replication competent forms of any of the listed micro- organisms. .
Recommended publications
  • Assessing Neurotoxicity of Drugs of Abuse
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Assessing Neurotoxicity of Drugs of Abuse 136 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Assessing Neurotoxicity of Drugs of Abuse Editor: Lynda Erinoff, Ph.D. NIDA Research Monograph 136 1993 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGMENT This monograph is based on the papers and discussions from a technical review on “Assessing Neurotoxicity of Drugs of Abuse” held on May 20-21, 1991, in Bethesda, MD. The technical review was sponsored by the National Institute on Drug Abuse (NIDA). COPYRIGHT STATUS NIDA has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Biosafety Level 1 and Rdna Training
    Biosafety Level 1and rDNA Training Office of Biological Safety Biosafety Level 1 and rDNA Training • Difference between Risk Group and Biosafety Level • NIH and UC policy on recombinant DNA • Work conducted at Biosafety Level 1 • UC Code of Conduct for researchers Biosafety Level 1 and rDNA Training What is the difference between risk group and biosafety level? Risk Groups vs Biosafety Level • Risk Groups: Assigned to infectious organisms by global agencies (NIH, CDC, WHO, etc.) • In US, only assigned to human pathogens (NIH) • Biosafety Level (BSL): How the organisms are managed/contained (increasing levels of protection) Risk Groups vs Biosafety Level • RG1: Not associated with disease in healthy adults (non‐pathogenic E. coli; S. cerevisiae) • RG2: Cause diseases not usually serious and are often treatable (S. aureus; Legionella; Toxoplasma gondii) • RG3: Serious diseases that may be treatable (Y. pestis; B. anthracis; Rickettsia rickettsii; HIV) • RG4: Serious diseases with no treatment/cure (Hemorrhagic fever viruses, e.g., Ebola; no bacteria) Risk Groups vs Biosafety Level • BSL‐1: Usually corresponds to RG1 – Good microbiological technique – No additional safety equipment required for biological work (may still need chemical/radiation protection) – Ability to destroy recombinant organisms (even if they are RG1) Risk Groups vs Biosafety Level • BSL‐2: Same as BSL‐1, PLUS… – Biohazard signs – Protective clothing (lab coat, gloves, eye protection, etc.) – Biosafety cabinet (BSC) for aerosols is recommended but not always required – Negative airflow into room is recommended, but not always required Risk Groups vs Biosafety Level • BSL‐3: Same as BSL‐2, PLUS… – Specialized clothing (respiratory protection, Tyvek, etc.) – Directional air flow is required.
    [Show full text]
  • Biosafety Manual 2017
    Biosafety Manual 2017 Revised 6/2017 Policy Statement It is the policy of Northern Arizona University (NAU) to provide a safe working environment. The primary responsibility for insuring safe conduct and conditions in the laboratory resides with the principal investigator. The Office of Biological Safety is committed to providing up-to-date information, training, and monitoring to the research and biomedical community concerning the safe conduct of biological, recombinant, and acute toxin research and the handling of biological materials in accordance with all pertinent local, state and federal regulations, guidelines, and laws. To that end, this manual is a resource, to be used in conjunction with the CDC and NIH guidelines, the NAU Select Agent Program, Biosafety in Microbiological and Biomedical Laboratories (BMBL), and other resource materials. Introduction This Biological Safety Manual is intended for use as a guidance document for researchers and clinicians who work with biological materials. It should be used in conjunction with the Laboratory-Specific Safety Manual, which provides more general safety information. These manuals describe policies and procedures that are required for the safe conduct of research at NAU. The NAU Personnel Policy on Safety 5.03 also provides guidance for safety in the workplace. Responsibilities In the academic research/teaching setting, the principal investigator (PI) is responsible for ensuring that all members of the laboratory are familiar with safe research practices. In the clinical laboratory setting, the faculty member who supervises the laboratory is responsible for safety practices. Lab managers, supervisors, technicians and others who provide supervisory roles in laboratories and clinical settings are responsible for overseeing the safety practices in laboratories and reporting any problems, accidents, and spills to the appropriate faculty member.
    [Show full text]
  • Biological Safety Guide
    Biological Safety Guide Biological Safety Office Environmental Health & Safety Division 1405 Goss Lane, CI 1001 Augusta, Georgia 30912 Revised: February 2014 STATEMENT OF AUTHORITY Upon publication of these procedures, the Institutional Biosafety Committee (IBC) of the Georgia Regents University, is hereby authorized to act as agent for the Georgia Regents University in matters of review, control, and mediation arising from the use or proposed use of biological materials, including recombinant DNA, at the Georgia Regents University. A statement of composition of the Institutional Biosafety Committee and a delineation of authority is included in the following pages of this text. Furthermore, it is hereby declared that the Biological Safety Office of the Georgia Regents University derives its authority directly from the Office of the President of the Georgia Regents University in all matters involving biological safety and/or violations of accepted rules of practice as described herein. The Biosafety Officer is hereby granted the authority to immediately suspend a project which is found to be a threat to health, property, or the environment. ____________________________________ __________________ James J. Rush, Jr, Esq Date Chief Integrity Officer Georgia Regents University Georgia Regents University Biosafety Guide-January 2012 Statement of Authority TABLE OF CONTENTS List of Abbreviations .............................................................................. viii Forward .................................................................................................
    [Show full text]
  • Alphabetical Listing of Export Restricted Biological Items
    Alphabetical Listing of Export Restricted Biological Items There are two sets of regulations for export restricted biological items, the International Traffic in Arms Regulations (ITAR) from Dept. of State and the Export Administration Regulations from Dept. of Commerce. These items require export licenses to all countries. Licensing takes about 6 weeks. Fines are $250,000 to $1,094,010 per violation. See the Export Control website within the Office of Research at: https://research.uci.edu/ref/export-controls/index.html These listed items are controlled for export regardless of quantity or attenuation, genetic elements or genetically modified organisms for such agents or “toxins”, including small quantities or attenuated strains of select biological agents or “toxins” that are excluded from the lists of select biological agents or “toxins” by APHIS, CDC, or DHHS. Under the ITAR, Biological agents and biologically derived substances specifically developed, configured, adapted, or modified for the purpose of increasing their capability to produce casualties in humans or livestock, degrade equipment or damage crops are controlled under CATEGORY XIV—TOXICOLOGICAL AGENTS, INCLUDING CHEMICAL AGENTS, BIOLOGICAL AGENTS, AND ASSOCIATED EQUIPMENT. Please note that there are proposed regulations on this category that if they become final will impact the listing of biologicals. See Part 121 United States Munitions List Category XIV. Certain precursor chemicals, Biosafety gear, and lab equipment are also export restricted see Categories 1 & 2 of the
    [Show full text]
  • AM 1/06 Mont⁄Ě
    REVIEW ARTICLE PROTEIN BIOTOXINS OF MILITARY SIGNIFICANCE Jiří Patočka1, Ladislav Středa2 University of Defence, Faculty of Military Health Sciences, Czech Republic: Department of Toxicology1; University of South Bohemia, Faculty of Health and Social Studies, Czech Republic: Department of Radiology and Toxicology1; State Office for Nuclear Safety, Czech Republic: Department for Control of the Prohibition of Chemical Weapons2 Summary: There is a spectrum of several threat agents, ranging from nerve agents and mustard agents to natural substan- ces, such as biotoxins and new, synthetic, bioactive molecules produced by the chemical industry, to the classical biologi- cal warfare agents. The new, emerging threat agents are biotoxins produced by animals, plants, fungi, and bacteria. Many types of organisms produce substances that are toxic to humans. Examples of such biotoxins are botulinum toxin, tetanus toxin, and ricin. Several bioactive molecules produced by the pharmaceutical industry can be even more toxic than are the classical chemical warfare agents. Such new agents, like the biotoxins and bioregulators, often are called mid-spectrum agents. The threat to humans from agents developed by modern chemical synthesis and by genetic engineering also must be considered, since such agents may be more toxic or more effective in causing death or incapacitation than classical war- fare agents. By developing effective medical protection and treatment against the most likely chemical and mid-spectrum threat agents, the effects of such agents in a war scenario or following a terrorist attack can be reduced. Toxin-mediated di- seases have made humans ill for millennia. Unfortunately, the use of biological agents as weapons of terror has now been realized, and separating naturally occurring disease from bioterroristic events has become an important public health goal.
    [Show full text]
  • Integrating the Neurobiology of Schizophrenia
    International REVIEW OF Neurobiology Volume 78 International REVIEW OF Neurobiology Volume 78 SERIES EDITORS RONALD J. BRADLEY Department of Psychiatry, College of Medicine The University of Tennessee Health Science Center Memphis, Tennessee, USA R. ADRON HARRIS Waggoner Center for Alcohol and Drug Addiction Research The University of Texas at Austin Austin, Texas, USA PETER JENNER Division of Pharmacology and Therapeutics GKT School of Biomedical Sciences King’s College, London, UK EDITORIAL BOARD ERIC AAMODT HUDA AKIL PHILIPPE ASCHER MATTHEW J. DURING DONARD S. DWYER DAVID FINK MARTIN GIURFA MICHAEL F. GLABUS PAUL GREENGARD BARRY HALLIWELL NOBU HATTORI JON KAAS DARCY KELLEY LEAH KRUBITZER BEAU LOTTO KEVIN MCNAUGHT MICAELA MORELLI JOSE´ A. OBESO JUDITH PRATT CATHY J. PRICE EVAN SNYDER SOLOMON H. SNYDER JOHN WADDINGTON STEPHEN G. WAXMAN Integrating the Neurobiology of Schizophrenia EDITED BY ANISSA ABI-DARGHAM Department of Psychiatry, Columbia College of Physicians and Surgeons New York State Psychiatric Institute Columbia University, New York, USA OLIVIER GUILLIN Unite´ de Psychiatrie CHU ch. Nicolle Rouen, France AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 525 B Street, Suite 1900, San Diego, California 92101-4495, USA 84 Theobald’s Road, London WC1X 8RR, UK This book is printed on acid-free paper. Copyright ß 2007, Elsevier Inc. All Rights Reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the Publisher.
    [Show full text]
  • Category 1—Page 1
    Commerce Control List Supplement No. 1 to Part 774 Category 1—page 1 CATEGORY 1 - SPECIAL MATERIALS AND to the ITAR” (see 22 CFR parts 120 through RELATED EQUIPMENT, CHEMICALS, 130, including USML Category XXI). (2) “MICROORGANISMS,” AND “TOXINS” See also 1C009. Related Definitions: N/A Note: The Food and Drug Administration Items: (FDA) and the Drug Enforcement Administration (DEA) may control exports of items subject to the a. Seals, gaskets, sealants or fuel bladders, EAR and on the Commerce Control List. BIS “specially designed” for “aircraft” or aerospace provides cross references to these other agency use, made from more than 50% by weight of any controls for convenience only. Therefore, please of the materials controlled by 1C009.b or consult relevant FDA and DEA regulations for 1C009.c; guidance related to the item you wish to export and do not rely solely on the EAR for information b. [Reserved] about other agency export control requirements. See Supplement No. 3 to part 730 (Other U.S. Government Departments and Agencies with 1A002 “Composite” structures or laminates, Export Control Responsibilities) for as follows (see List of Items Controlled). more information. License Requirements A. “END ITEMS,” “EQUIPMENT,” Reason for Control: NS, NP, AT “ACCESSORIES,” “ATTACHMENTS,” “PARTS,” “COMPONENTS,” AND Control(s) Country Chart “SYSTEMS” (See Supp. No. 1 to part 738) 1A001 “Parts” and “components” made from NS applies to entire entry NS Column 2 fluorinated compounds, as follows (see List of NP applies to 1A002.b.1 in NP Column 1 Items Controlled). the form of tubes with an inside diameter between 75 License Requirements mm and 400 mm AT applies to entire entry AT Column 1 Reason for Control: NS, AT Reporting Requirements Country Chart Control(s) (See Supp.
    [Show full text]
  • Bioterrorism
    BIOTERRORISM Edited by Stephen A. Morse Bioterrorism Edited by Stephen A. Morse Published by InTech Janeza Trdine 9, 51000 Rijeka, Croatia Copyright © 2012 InTech All chapters are Open Access distributed under the Creative Commons Attribution 3.0 license, which allows users to download, copy and build upon published articles even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. After this work has been published by InTech, authors have the right to republish it, in whole or part, in any publication of which they are the author, and to make other personal use of the work. Any republication, referencing or personal use of the work must explicitly identify the original source. As for readers, this license allows users to download, copy and build upon published chapters even for commercial purposes, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. Notice Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials, instructions, methods or ideas contained in the book. Publishing Process Manager Sasa Leporic Technical Editor Teodora Smiljanic Cover Designer InTech Design Team First published March, 2012 Printed in Croatia A free online edition of this book is available at www.intechopen.com Additional hard copies can be obtained from [email protected] Bioterrorism, Edited by Stephen A.
    [Show full text]
  • Download the Full PDF Here
    Oct-Nov-Dec 2015 Volume 16, Issue 4 Targeting Trends Reporting the latest news in Molecular Surgery A specific immunotoxin elucidates a causal role of striatal cholinergic system in behavioral flexibility by Sho Aoki and Jeffery R. Wickens Neurobiology Research Unit, Okinawa Institute of Science and Technology, 1919-1 Tancha, Onna, Kunigami, Okinawa 904-0495, Japan Behavioral flexibility is broadly defined as the ability to change behavioral strategy, Inside this issue: according to a change of governing rules. Accumulated evidence suggests the involvement of particular brain areas such as prefrontal cortex and striatum in this function, in which Targeting Topics Scientific References 3-5 specific brain regions play their own roles. An extension of understanding on neural substrates mediating behavioral flexibility needs a next step beyond the specificity of Targeting Talk brain regions: the specific role of different neuronal subtypes. A method utilizing specific Questions & Answers 5 neurotoxins enabled us to target and elucidate the role of neurochemically-specific Targeting Tools 7 neurons in this ability. In our recent study, 1 we demonstrated a causal role of rat Targeting Teaser cholinergic interneurons in the striatum in behavioral flexibility, using a new specific Word Quiz 8 immunotoxin targeting neurons containing choline acetyltransferase (ChAT). Comparing non-selective neuronal labeling and specific immunostaining of ChAT neurons indicated that local injections of the immunotoxin successfully and selectively damaged cholinergic neurons (Fig. 1). This result is consistent with a previous study that used Anti-ChAT-SAP Highlights to study the medial prefrontal cortex (Cat. #IT-42). 2 ◆ NEW! (pg 2) Using the selective lesion, we compared intact rats injected with saline and rats Mono-Biotin Saporin without cholinergic interneurons of either dorsomedial or ventral striatum in a set-shifting 3 ◆ Teaser Winners (pg 2) task.
    [Show full text]
  • Table 4: Protective Action Criteria (PAC) Rev. 29 Based on Applicable
    Table 4: Protective Action Criteria (PAC) Rev. 29a based on applicable 60-minute AEGLs, ERPGs, or TEELs. The chemicals are 3 listed in alphabetical order and the values are presented in mg/m . June 2018 Table 4 is an alphabetical list of the chemical substances and their corresponding PAC values in mass per unit volume (mg/m3). The conversion of ppm to mg/m3 was carried out assuming normal temperature and pressure, 25°C and 760 mm Hg. The columns presented in Table 4 provide the following information: Heading Definition No. The ordered numbering of the chemicals as they appear in this alphabetical listing Chemical Name The name of the chemical substance submitted to the PAC development team CASRN The Chemical Abstracts Service Registry Number1 for this chemical PAC-1 Based on the applicable AEGL-1, ERPG-1, or TEEL-1 value PAC-2 Based on the applicable AEGL-2, ERPG-2, or TEEL-2 value PAC-3 Based on the applicable AEGL-3, ERPG-3, or TEEL-3 value Chemicals for which AEGLs are available have their chemical name, CASRN, and AEGL values displayed in a bolded and larger font. Chemicals for which ERPGs are available, but not AEGLs, have their chemical name, CASRN, and ERPG values displayed in a bolded font. Chemicals for which TEELs are available, but no AEGLs or ERPGs, have their chemical name, CASRN, and values displayed using a regular font. Additional information on PAC values and TEEL values and links to other sources of information is provided on the Subcommittee on Consequence Assessment and Protective Actions (SCAPA) webpage at http://orise.orau.gov/emi/scapa/default.htm.
    [Show full text]
  • AM 1/06 Mont⁄Ì
    REVIEW ARTICLE PROTEIN BIOTOXINS OF MILITARY SIGNIFICANCE Jiří Patočka1, Ladislav Středa2 University of Defence, Faculty of Military Health Sciences, Czech Republic: Department of Toxicology1 and University of South Bohemia, Faculty of Health and Social Studies, Czech Republic: Department of Radiology and Toxicology1 State Office for Nuclear Safety, Czech Republic: Department for Control of the Prohibition of Chemical Weapons2 Summary: There is a spectrum of several threat agents, ranging from nerve agents and mustard agents to natural substan- ces, such as biotoxins and new, synthetic, bioactive molecules produced by the chemical industry, to the classical biologi- cal warfare agents. The new, emerging threat agents are biotoxins produced by animals, plants, fungi, and bacteria. Many types of organisms produce substances that are toxic to humans. Examples of such biotoxins are botulinum toxin, tetanus toxin, and ricin. Several bioactive molecules produced by the pharmaceutical industry can be even more toxic than are the classical chemical warfare agents. Such new agents, like the biotoxins and bioregulators, often are called mid-spectrum agents. The threat to humans from agents developed by modern chemical synthesis and by genetic engineering also must be considered, since such agents may be more toxic or more effective in causing death or incapacitation than classical war- fare agents. By developing effective medical protection and treatment against the most likely chemical and mid-spectrum threat agents, the effects of such agents in a war scenario or following a terrorist attack can be reduced. Toxin-mediated di- seases have made humans ill for millennia. Unfortunately, the use of biological agents as weapons of terror has now been realized, and separating naturally occurring disease from bioterroristic events has become an important public health goal.
    [Show full text]